Top 10 Companies in the Newborn Screening and Genetic Services Market (2026): Market Leaders Driving Early Detection

MARKET INSIGHTS

The global newborn screening and genetic services market size was valued at USD 1.35 billion in 2024. The market is projected to grow from USD 1.47 billion in 2025 to USD 2.84 billion by 2032, exhibiting a CAGR of 9.2% during the forecast period.

Newborn screening and genetic services encompass a range of diagnostic tests designed to identify genetic, metabolic, and congenital disorders in infants shortly after birth. These services include dry blood spot tests, hearing screening, critical congenital heart disease (CCHD) screening, and other specialized genetic analyses. The primary objective is early detection to enable timely intervention and improved health outcomes.

The market growth is driven by increasing awareness of genetic disorders, government mandates for newborn screening programs, and technological advancements in genomics. Rising investments in healthcare infrastructure across emerging economies and the integration of next‑generation sequencing (NGS) into neonatal testing protocols further accelerate adoption. Key players such as PerkinElmer, Bio‑Rad Laboratories, and Natus Medical are expanding their portfolios through strategic partnerships and innovations in high‑throughput screening solutions.

Newborn Screening and Genetic Services Market – View in Detailed Research Report

Top 10 Companies

1. PerkinElmer (USA)
   Key Offering: Integrated newborn screening platform – instruments, reagents, and data‑management software.
   PerkinElmer’s portfolio supports every stage of the screening pipeline, from sample collection to result interpretation, and its recent acquisitions in genomics have broadened its genetic panel coverage.
   Sustainability & Growth Initiatives: Investment in low‑cost NGS modules and a partnership with public health agencies to expand screening in underserved regions.
   • Global reach through established distribution networks.
   • Continuous R&D pipeline for next‑generation assays.
   • Commitment to data privacy and secure cloud analytics.
2. Bio‑Rad Laboratories (USA)
   Key Offering: Comprehensive test kits and quality‑control reagents for metabolic and genetic disorders.
   Bio‑Rad’s focus on modular, scalable solutions aligns with the needs of both large national programs and smaller regional labs.
   Sustainability & Growth Initiatives: Development of low‑sample‑volume assays and integration with digital health platforms.
   • Strong presence in emerging markets.
   • Strategic alliances with academic research centers.
   • Dedicated support for laboratory accreditation processes.
3. Natus Medical (USA)
   Key Offering: Hearing screening equipment and newborn screening software.
   Natus has leveraged its acquisition by ArchiMed to broaden its footprint in audiology and newborn diagnostics.
   Sustainability & Growth Initiatives: Expansion of tele‑screening capabilities and AI‑driven interpretation tools.
   • Robust global service network.
   • Focus on patient‑centric data sharing.
   • Investment in workforce training for new technologies.
4. Trivitron Healthcare (India)
   Key Offering: Cost‑effective newborn screening kits and point‑of‑care devices.
   Trivitron’s market strategy centers on affordability and rapid deployment in high‑volume settings.
   Sustainability & Growth Initiatives: Local manufacturing to reduce supply‑chain costs and partnerships with government health programs.
   • Strong presence in South and South‑East Asia.
   • Focus on scalable, modular solutions.
   • Collaboration with NGOs for outreach.
5. Masimo Corporation (USA)
   Key Offering: Pulse oximetry devices for critical congenital heart disease (CCHD) screening.
   Masimo’s technology delivers rapid, non‑invasive assessment of neonatal oxygen saturation, a critical early warning for cardiac anomalies.
   Sustainability & Growth Initiatives: Development of integrated screening suites that combine oximetry with biochemical assays.
   • High adoption in U.S. and European hospitals.
   • Strategic collaborations with national screening programs.
   • Commitment to device miniaturization.
6. Agilent Technologies (USA)
   Key Offering: Analytical instrumentation for confirmatory testing – mass spectrometry and chromatography systems.
   Agilent’s precision instruments support the verification phase of newborn screening and the growing demand for complex genetic diagnostics.
   Sustainability & Growth Initiatives: Integration of AI‑based data analytics into instrument software.
   • Global laboratory presence.
   • Focus on high‑throughput solutions.
   • Partnerships with genomic service providers.
7. Waters Corporation (USA)
   Key Offering: Liquid chromatography‑mass spectrometry (LC‑MS) systems for metabolic screening.
   Waters’ instruments are widely used in reference laboratories and support the expansion of expanded panels.
   Sustainability & Growth Initiatives: Development of automated workflows and cloud‑based data management.
   • Robust support for regulatory compliance.
   • Investment in instrument miniaturization.
   • Focus on reducing reagent consumption.
8. AB Sciex LLC (USA)
   Key Offering: High‑resolution mass spectrometry for targeted metabolic assays.
   AB Sciex’s technology offers high sensitivity and rapid turnaround, meeting the needs of high‑volume screening labs.
   Sustainability & Growth Initiatives: Integration of AI‑driven variant calling and data sharing platforms.
   • Strong foothold in North America.
   • Partnerships with academic research institutions.
   • Focus on cost‑effective instrument maintenance.
9. Thermo Fisher Scientific (USA)
   Key Offering: Next‑generation sequencing platforms and bioinformatics solutions for newborn screening.
   Thermo Fisher’s portfolio spans from sample preparation to data analysis, positioning it as a one‑stop shop for comprehensive screening programs.
   Sustainability & Growth Initiatives: Development of low‑sample‑volume, high‑throughput sequencing workflows and cloud‑based analytics.
   • Extensive global service network.
   • Investment in AI‑powered diagnostics.
   • Strategic alliances with national screening programs.
10. Roche Diagnostics (Switzerland)
    Key Offering: Integrated newborn screening solutions, including immunoassays and mass spectrometry platforms.
    Roche’s focus on diagnostic accuracy and rapid result delivery aligns with the needs of both clinical laboratories and public health agencies.
    Sustainability & Growth Initiatives: Expansion of digital health integration and real‑time data reporting.
    • Strong presence in Europe and emerging markets.
    • Partnerships with governmental health ministries.
    • Commitment to continuous innovation in assay development.

Download FREE Sample Report

Get Full Report

Market Outlook

Base year: 2025 – USD 1.47 billion. Estimated 2026 – USD 1.60 billion. Forecast 2034 – USD 2.84 billion. The trajectory underscores a steady expansion driven by regulatory support, technology integration, and growing demand for personalized care pathways.

Future Trends

1. Integration of AI and Big Data Analytics – Predictive models will refine variant interpretation, reduce false positives, and streamline laboratory workflows.
2. Expansion into Emerging Economies – Tailored, low‑cost screening kits and scalable implementation models will unlock significant growth in Asia, Latin America, and Africa.
3. Shift Toward Personalized Medicine – Early genetic insights will inform lifelong health management, opening opportunities for companion diagnostics and targeted therapeutics.
4. Consolidation and Strategic Partnerships – M&A activity will continue to shape the competitive landscape, driving innovation and expanding geographic reach.